A method for using a sonic wave to influence material in a target structure requires using a confined plasma antenna to generate an electromagnetic carrier wave, λ. The confined plasma antenna also pulses the carrier wave at a sonic frequency, f, to create a sonic wave. In detail, pulsing the carrier wave results in a sequential plurality of solitons which are separated from each other by a periodicity p, wherein λ«p. For the present invention, f is selected to resonate with a material (e.g. a cellular structure) in a target structure (e.g. a patient).

The present invention relates to a device, system and a method for high pressure shockwave treatment of biological tissue having a large treatment zone and in particular to such a device, system and method in which a large biological treatment area in treated in a non-drug, non-surgical treatment protocol utilizing ballistic shockwave generating device.

The present invention generally relates to improved medical devices, systems, and methods, with exemplary embodiments providing improved cooling treatment probes and cooling treatment methods and systems. In some embodiments, freezing of the skin may be desirable to effect the hypopigmentation of the skin of the patient. Generally, embodiments may limit supercooling of the skin of the patient during a cooling treatment. Additionally, embodiments may limit adverse side effects such as hyperpigmentation. It has been found that the freezing behavior (frequency and time to freeze) can be modified by adjusting the thermal parameters of the cooling applicator. Accordingly, in some aspects of the invention, a method of treating the skin may be provided where the thermal parameters of the cooling applicator are adjusted during treatment.

The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

A therapeutic device for treating one or more conditions associated with a user's nasal cavities, sinuses, and/or ear canals includes a housing having an opening, an acoustic vibrator within the housing that is operable to provide an acoustic vibration to the user, a fan within the housing that is operable to provide a pressure to the user and a power supply that provides power to the acoustic vibrator and the fan. A mask is connected to the housing at the opening and includes a nasal interface appliable around the nose of the user, a nasal chamber in which the user's nostrils are located and an aperture through which the fan delivers the pressure.

An intracorporeal pressure shock wave includes an expandable pressure shock wave reflector at the distal end of an intracorporeal catheter to direct shock waves from a shock wave generator within a human or animal blood vessel or body lumen.

A method of treating red blood cells of a human patient has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting a vascular system containing red blood cells and surrounding muscle tissue peripherally through an extremity of a patient to the acoustic shock waves by stimulating the extremity wherein the extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. The methods also treat muscle tissue of aging patients, from muscle regeneration or athletes for legal performance enhancement without drugs.

A method of treating red blood cells of a human patient has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting a vascular system containing red blood cells and surrounding muscle tissue peripherally through an extremity of a patient to the acoustic shock waves by stimulating the extremity wherein the extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. The methods also treat muscle tissue of aging patients, from muscle regeneration or athletes for legal performance enhancement without drugs.

The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

A waveguide that is configured to focus ballistic shockwaves by harnessing the propagation speed of an acoustic wave through different materials by controlling the geometry and the materials forming the waveguide through which the ballistic shockwave is travelling so as to focus the ballistic shockwaves at a focal zone.